MedTrace Logo

The Effects of Nitazoxanide in Hepatic Encephalopathy

NCT02334163 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-01-08

No results posted yet for this study

Summary

Evaluating the efficacy and safety of nitazoxanide in comparison to standard treatment in patients with grade II-III hepatic encephalopathy (HE). Also, Evaluating the effect of administering nitazoxanide on the improvement of patient's quality of life.

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Nitazoxanide

500 mg nitazoxanide tablets twice daily

DRUG

Oral lactulose

Oral lactulose (65%)

DRUG

Metronidazole

250 mg metronidazole tablets every 8 hours

DRUG

Rifaximine

Two 200 mg rifaximine tablets every 8 hours

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

  • Al-Azhar University

    collaborator OTHER

Principal Investigators

  • Asmaa A. Elrakaybi, Bachelor · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-02-28
Completion
2015-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334163 on ClinicalTrials.gov